Bispecific anti-c-Met/PD-1

N/A

Report date: 2025/02/14 11:13:17

Base Information

Drug NameBispecific anti-c-Met/PD-1

Drug Alias NameBispecific anti-PD-1/c-Met

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-Hepatocyte growth factor receptorAnti-PD-1

TargetsHepatocyte growth factor receptorProgrammed cell death protein 1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesFudan University

China Registration ClassN/A

Develop Information

Active CompaniesFudan University

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A